Credibility that holds up under scrutiny from investors and scientific partners even without a commercial product, a pipeline presentation precise enough to survive comparison against public trial registries, and a platform sized to what the actual team can maintain rather than an enterprise build.
The best biotech sites state what is actually known precisely, without the promotional framing that erodes trust with a sophisticated reader who checks claims against public sources. Restraint reads as more credible than enthusiasm in this specific audience.
Investors and partners routinely verify pipeline claims against registries like ClinicalTrials.gov — see pipeline page for what precise, verifiable presentation actually looks like.
A platform the current, usually small, team can maintain independently, built to extend through future funding rounds rather than requiring a rebuild at each stage — see biotech for the fuller picture of what we build for this stage.
Yes, meaningfully — a Series A company is usually building credibility with a much narrower audience of investors and potential partners rather than a broad commercial one, which changes what the site needs to prioritise. See website for a Series A biotech for that stage-specific answer, including what to include, and what to deliberately leave out, at that stage.
Where publications exist and strengthen your credibility with a scientifically literate audience, yes — omitting them can look like you have less to show than you do. See scientific content hub for how that kind of content typically gets structured so it stays accessible without overwhelming a visitor who isn’t a specialist in your specific area.
Enough to look credible and current, without becoming a distraction from the science and pipeline substance a sophisticated reader is there to evaluate. Overly elaborate design can even work against you with an investor or partner audience that reads polish without substance as a warning sign rather than reassurance.
It typically spans investors, potential pharma partners, prospective employees, and sometimes patients or advocacy groups, depending on your pipeline stage and therapeutic area. Each group looks for different things — investors want pipeline clarity and team credibility, partners want scientific depth, candidates want culture signals — so the site needs to serve several distinct paths rather than one generic homepage message.
Tell us your stage and pipeline and we will tell you how we would approach it.